Polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof

US8586599B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Axel Becker · Altrip, DE
• Clemens Kuehn · Darmstadt, DE
• Christoph Saal · Otzberg, DE
• Oliver Schadt · Rodenbach, DE
• Dieter Dorsch · Ober-Ramstadt, DE
• Eva Kriegbaum · Darmstadt, DE
• Frank Stieber · Heidelberg, DE
• Cristina Donini · Mandello del Lario, IT

Key dates

• Filing date: Nov 24, 2009
• Grant date: Nov 19, 2013
• Expiry date: Nov 24, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate, its solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.